{"organizations": [], "uuid": "24c516fc2e3fa30d730dfe4bb0c1f249d024006e", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180108.html", "section_title": "Archive News &amp; Video for Monday, 08 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-exelixis-enters-into-exclusive-col/brief-exelixis-enters-into-exclusive-collaboration-and-license-agreement-with-stemsynergy-therapeutics-idUSFWN1P30LQ", "country": "US", "domain_rank": 408, "title": "BRIEF-Exelixis Enters Into Exclusive Collaboration And License Agreement With Stemsynergy Therapeutics", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.06, "site_type": "news", "published": "2018-01-08T21:23:00.000+02:00", "replies_count": 0, "uuid": "24c516fc2e3fa30d730dfe4bb0c1f249d024006e"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-exelixis-enters-into-exclusive-col/brief-exelixis-enters-into-exclusive-collaboration-and-license-agreement-with-stemsynergy-therapeutics-idUSFWN1P30LQ", "ord_in_thread": 0, "title": "BRIEF-Exelixis Enters Into Exclusive Collaboration And License Agreement With Stemsynergy Therapeutics", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "exelixis inc", "sentiment": "negative"}, {"name": "exelixis", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 8 (Reuters) - Exelixis Inc:\n* EXELIXIS - ENTERED INTO EXCLUSIVE COLLABORATION AND LICENSE AGREEMENT WITH STEMSYNERGY THERAPEUTICS\n* EXELIXIS INC- AGREEMENT FOR DISCOVERY AND DEVELOPMENT OF NOVEL ONCOLOGY COMPOUNDS TARGETING CASEIN KINASE 1 ALPHA\n* EXELIXIS INC- WILL PAY STEMSYNERGY UPFRONT PAYMENT OF $3 MILLION AND UP TO $3.5 MILLION IN INITIAL RESEARCH AND DEVELOPMENT FUNDING\n* EXELIXIS INC- CO WILL BE SOLELY RESPONSIBLE FOR COMMERCIALIZATION OF PRODUCTS THAT ARISE FROM COLLABORATION Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-08T21:23:00.000+02:00", "crawled": "2018-01-09T17:05:09.008+02:00", "highlightTitle": ""}